Company / R&D Expense
Bausch & Lomb Corp R&D Expense History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$371.0M
FY2025
5-year range
$271.0M / $371.0M
FY2021-FY2025
Trend
+8.2%
vs FY2024
Sector context
#20 of 105
Health Care
What the data says
Bausch & Lomb Corp's r&d expense of $371M is higher than 81% of companies in the Health Care sector (FY2025). R&D Expense has increased for 5 consecutive years, from $253M in FY2020 to $371M in FY2025.
Based on SEC 10-K filings.
$371M in FY2025 with a 5-year CAGR of +8.0%. Top quartile in the Health Care sector.
Improved from $324M to $371M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +6.5%
- 5-Year CAGR
- +8.0%
- 10-Year CAGR
- -
Sector benchmark
Top 19% in Health CareTop 19% of 105This company $371.0M Sector average $284.2M
▼
+30.5% above sector average
Key checks
Key Insights
- Bausch & Lomb Corp's r&d expense has grown for 5 consecutive years.
- 5-year CAGR of +8.0%, indicating consistent growth.
- In FY2025, r&d expense increased 8.2% year-over-year.
- Ranks #20 out of 105 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.74 (distress zone, below 1.8 threshold)
- Negative profit margin: -6.6%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $371.0M | +8.2% |
| FY2024 | $343.0M | +5.9% |
| FY2023 | $324.0M | +5.5% |
| FY2022 | $307.0M | +13.3% |
| FY2021 | $271.0M | +7.1% |
| FY2020 | $253.0M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026